Reduced immune responses to the Epstein-Barr virus may help explain the efficacy of anti-CD20 therapy in people with MS, per ...
Over 95% of the world's adult population is infected with Epstein-Barr virus (EBV), but most people never realize it. The infection often causes few symptoms and then stays in the body for life. But ...
In the news release, Pierre Fabre Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Tabelecleucel for the ...
A cross-sectional study shows that ocrelizumab selectively contracts EBV-specific CD4 T-cell immunity in multiple sclerosis ...
Dr. Glenn will discuss how Pinion is designing mRNA immunotherapeutics intended to help adults restore immune control to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results